Jump to content

Vascular-targeting agent

Add links
From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by Nono64 (talk | contribs) at 17:41, 31 October 2009 (cleanup). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.[1]

VTAs can be small-molecule or ligand-based.

Small-molecule VTAs include:

Clinical trials

Phase II : ZD6126, CA4P, DMXAA (ASA404), NPI-2358[2]

Phase III : ASA404

References

  1. ^ http://clincancerres.aacrjournals.org/cgi/reprint/10/2/415.pdf "Vascular Targeting Agents as Cancer Therapeutics" 2004
  2. ^ Conducted by Nereus Pharmaceuticals.
    Staff (2009), "Clinical Trials Update", Genetic Engineering & Biotechnology News, 29 (8): 58


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Vascular-targeting_agent&oldid=323132425"